



29 Emmons Drive Suite B-10 Princeton, NJ 08540

T (609) 538-8200 · F (609) 452-6467

## Overview

Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Our Specialized BioTherapeutics business segment is developing and commercializing HyBryte™ (SGX301 or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With a successful Phase 3 study completed, regulatory approval and commercialization for this product is being advanced initially in the U.S. Development programs in this business segment also include expansion of synthetic hypericin (SGX302) into psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention / treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn's disease (SGX203).

Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, and vaccine programs targeting both filoviruses (such as Marburg and Ebola) and coronaviruses (COVID-19; CiVax™). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. We are also developing SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Biomedical Advanced Research and Development Authority (BARDA), and the Defense Threat Reduction Agency (DTRA).

## Investment Highlights

- Diversified product portfolio spanning Specialized BioTherapeutics and Public Health Solutions
- Experienced management team and Board of Directors
- Multiple orphan (rare) disease and fast-track development programs with significant worldwide market potential in excess of \$2B annually worldwide
- Regulatory approval and commercialization plans for HyBryte™ for CTCL (successful Phase 3 study completed) are being pursued with NDA filing targeted H2 2022 and projected launch in H2 2023
  - ◇ U.S. annual peak sales projected at >\$90M with a concentrated sales force of ~20 reps
- Significant non-dilutive contract / grant funding provided by the government, including
  - ◇ NIAID contract awards have totaled ~\$30M to date in support of RiVax® development
  - ◇ NIAID grant award of ~\$1.5M supporting CiVax™ and Ebola virus vaccine development
- Exclusive collaborations with biotech, academia and government agencies
- Potential to be granted biodefense Priority Review Voucher, if FDA approval of medical countermeasure (MCM) is obtained

### Specialized BioTherapeutics

- **HyBryte™** to treat CTCL, representing a total addressable market > \$250M annually worldwide
- Synthetic hypericin (active ingredient in HyBryte™) to treat mild-to-moderate psoriasis (**SGX302**), representing a total addressable market > \$1B annually worldwide
- Oral BDP to treat inflammatory diseases of the GI tract, such as pediatric Crohn's disease (**SGX203**), representing markets > \$200M annually worldwide

### Public Health Solutions

- **ThermoVax®** — proprietary heat stabilization platform technology capable of eliminating cold chain production and storage concerns for vaccines — proof of concept demonstrated
- **RiVax®** — a world leader in ricin toxin vaccine research with NIH funding in excess of \$30M to date which has demonstrated significant survival results in a non-human primate model of ricin exposure
- **CiVax™** — subunit protein vaccine with non-human primate data supporting both immunogenicity and thermostability, specifically targeting SARS-CoV-2 (the cause of COVID-19)
- **Filovirus vaccines** — vaccines with demonstrated activity in non-human primates for ebola-like diseases, including Marburg virus for which there is no approved vaccine

[www.soligenix.com](http://www.soligenix.com)

Nasdaq: SNGX

Stock Snapshot  
as of 04/01/22

Market Cap:  
~\$31.8 Million

Stock Price: \$0.74

Avg Daily Vol (3M):  
~250K

Shares Outstanding:  
~43.0 Million

## Executive Team

Christopher J. Schaber, PhD  
*President & CEO*

Richard C. Straube, MD  
*Chief Medical Officer*

Oreola Donini, PhD  
*Chief Scientific Officer*

Jonathan Guarino, CPA  
*Chief Financial Officer*

## Board of Directors

Christopher J. Schaber, PhD  
*Chairman, President & CEO*

Gregg Lapointe, CPA  
*Director*

Diane Parks  
*Director*

Robert J. Rubin, MD  
*Director*

Jerome Zeldis, MD, PhD  
*Director*

## General Contact

Soligenix, Inc.  
29 Emmons Drive  
Suite B-10  
Princeton, NJ 08540  
Phone: (609) 538-8200  
Fax: (609) 452-6467  
[info@soligenix.com](mailto:info@soligenix.com)

## Specialized BioTherapeutics

Product Candidates*	Preclinical	Phase 1	Phase 2	Phase 3	Market
<b>HyBryte™ (SGX301 or synthetic hypericin)</b> Cutaneous T-Cell Lymphoma (CTCL)	ORPHAN & FAST TRACK DESIGNATION			Positive Phase 3 results	NDA in preparation
<b>SGX942 (dusquetide)</b> Oral Mucositis in Head & Neck Cancer**	FAST TRACK DESIGNATION			Evaluate combined datasets; 2 <sup>nd</sup> Phase 3 study required	
<b>SGX203 (beclomethasone dipropionate)</b> Pediatric Crohn's Disease**	ORPHAN & FAST TRACK DESIGNATION			Initiation contingent upon additional funding and/or partnership	
<b>SGX302 (synthetic hypericin)</b> Mild-to-Moderate Psoriasis				Positive proof of concept demonstrated in Phase 1/2 pilot study	

## Public Health Solutions\*\*

Product Candidates (FDA Animal Rule)*	Proof-of-Concept	IND	Phase 1	Phase 2/3	Market
<b>RiVax® + ThermoVax® – Vaccine</b> Ricin Toxin Pre-Exposure	ORPHAN & FAST TRACK DESIGNATION			NIH Contract Awards of <b>\$30M</b> to date; positive preclinical and clinical data	
<b>SGX943 (dusquetide) – Therapeutic</b> Emerging Infectious Disease	FAST TRACK		USG awards of <b>\$900,000</b> to date; positive proof of concept preclinical data		
<b>CiVax™ + ThermoVax® – Vaccine</b> COVID-19			NIH Grant Award of <b>\$1.5M</b> to date; positive preclinical data		
<b>Filovirus vaccines + ThermoVax®</b> Ebola/Marburg			NIH Grant Subaward of <b>\$700,000</b> to date; positive preclinical data		

Denotes funding in whole or in part by NIH, DTRA, BARDA and/or FDA \* Anticipated event and timing subject to COVID-19 disruption \*\* Potential value drivers dependent on continued government funding and/or other funding sources

## Specialized BioTherapeutics

HyBryte™ (SGX301) is a novel, first-in-class photodynamic therapy utilizing safe visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer which is topically applied to skin lesions and then activated by visible light. Combined with photoactivation, hypericin has demonstrated significant anti-proliferative effects on activated normal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. **A successful pivotal Phase 3 has been completed, demonstrating rapid onset of efficacy (within 6 weeks) and continued improvement with continued treatment,** achieving outcomes other therapies may require months-years to attain in 18 weeks, and similar efficacy against patches and plaques, where other treatments typically work on patches but not plaques. HyBryte™ was well-tolerated throughout the study, with a significantly improved adverse event rate compared to other second-line treatment options. Soligenix is advancing **towards regulatory approval and commercialization of HyBryte™ in the U.S.**, where peak annual U.S. sales projections exceed \$90M and the total addressable global market is estimated at approximately \$250M. As a chronic disease requiring repeat treatment with diagnosis and treatment governed by a targeted set of specialists at Centers of Excellence, the commercial footprint for HyBryte™ is expected to be highly concentrated. With its broad efficacy and excellent safety profile, HyBryte™ is expected to be a preferred treatment modality in a field characterized by treatments limited to second-line use due to their toxicity profiles. Based on its validated biologic activity, Soligenix has recently **expanded synthetic hypericin development into psoriasis (SGX302) and plans to initiate a Phase 2 study in 2022.**

Dusquetide is a novel, proprietary 5-amino acid IDR which reduces inflammation associated with activation of innate immunity while simultaneously enhancing resolution of infection and tissue damage. A recently completed Phase 3 study confirmed biological activity in the per protocol population but did not achieve statistical significance in the intent to treat population. Completed discussions with the UK regulatory authorities (MHRA) and a second Phase 3 study will be required.

Oral BDP (beclomethasone 17,21-dipropionate) is a highly potent, topically active corticosteroid that is being developed for the treatment of pediatric Crohn's disease (SGX203). **A Phase 3 pivotal study has been cleared through FDA.**

## Public Health Solutions

The World Health Organization (WHO) reports that as much as 50% of all global vaccine doses are wasted because vaccines are not kept within required temperature ranges, adversely affecting both potency and efficacy. Elimination of the cold chain would generate significant savings in storage and distribution. Soligenix's thermostability technology, ThermoVax®, is a novel, proprietary method of stabilizing vaccines so that they can be maintained at temperatures exceeding 40 degrees Celsius.

Soligenix is currently developing biodefense MCMs pursuant to the Project BioShield Act and the BARDA Strategic Plan for repurposing and / or inclusion in the US government's Strategic National Stockpile. Its ricin toxin vaccine, RiVax®, which uses ThermoVax®, has demonstrated statistically significant survival results in a lethal aerosol exposure non-human primate (NHP) model and positive Phase 1 clinical trial results demonstrating that the vaccine is safe and induces antibodies against ricin in humans. The ThermoVax® technology is also being applied to a filovirus vaccine with proven activity in NHPs against both Marburg virus and 2 variants of Ebola virus, and to a potential coronavirus vaccine, CiVax™, to address COVID-19. **A contract grant from NIAID (~\$1.5M) is funding CiVax™ and ThermoVax® development activities.** Soligenix has demonstrated statistically significant efficacy with SGX943, its novel IDR technology using dusquetide as the active ingredient, against melioidosis and is **continuing to evaluate SGX943 against biodefense pathogens under a \$600,000 subaward from DTRA.**